AXQ Capital LP Buys 16,277 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• AXQ Capital more than doubled its Halozyme stake in the second quarter, buying 16,277 additional shares to own 30,831 shares valued at approximately $2.4 million. Institutional investors and hedge funds collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 beating estimates of $1.79 and revenue of $481 million surpassing expectations of $402.28 million; revenue increased 47.7% year over year.
• Shares opened at $110.76, near their 12-month high, while analyst sentiment remained favorable with a “Moderate Buy” consensus. However, insiders—including the CEO—have sold shares under pre-arranged trading plans, with insiders selling 32,478 shares last quarter.

AXQ Capital LP raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 111.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,831 shares of the biopharmaceutical company's stock after acquiring an additional 16,277 shares during the quarter. AXQ Capital LP's holdings in Halozyme Therapeutics were worth $2,413,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC increased its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC increased its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares in the last quarter. MidFirst Bank acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics in the 2nd quarter valued at $28,000. Finally, Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 1.0%

Shares of HALO opened at $110.76 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $111.15. The firm has a market capitalization of $12.57 billion, a PE ratio of 33.06, a price-to-earnings-growth ratio of 0.43 and a beta of 0.88. The stock's fifty day simple moving average is $90.05 and its 200-day simple moving average is $75.58.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 7.98 earnings per share for the current year.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 32,478 shares of company stock valued at $3,076,604. 2.50% of the stock is currently owned by insiders.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research raised its FY2026 EPS estimate to $8.24 from $7.56, above the $7.75 consensus, and increased its FY2027 estimate to $9.01 from $8.96. It also lifted estimates for Q4 2026, Q1 2027, Q4 2027, Q1 2028, and Q2 2028. The revisions reinforce expectations for continued earnings growth at Halozyme. MarketBeat Halozyme estimates
• Positive Sentiment: Analyst maintains Buy rating and raises valuation target: HC Wainwright reaffirmed its Buy rating and set a $115 price target, implying additional upside from the recent trading level. Benzinga analyst update
• Positive Sentiment: Stock reaches a new one-year high: The milestone reflects strong investor momentum and growing confidence in Halozyme’s commercial and earnings outlook. Halozyme reaches new one-year high
• Neutral Sentiment: Upcoming investor conferences: CEO Helen Torley and CFO Darren Snellgrove are scheduled to participate in conferences and meet with investors. The events could provide updates on ENHANZE and Halozyme’s broader drug-delivery portfolio, but no new financial guidance was announced. Halozyme investor conferences announcement
• Negative Sentiment: Some longer-term estimates were reduced: Zacks lowered its Q3 2027 EPS forecast to $2.16 from $2.26 and FY2028 EPS to $10.06 from $10.21. These modest cuts partially offset the broader set of upward revisions, though the estimates still imply substantial future earnings growth.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HALO. Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.